Daiichi Sankyo, Roche deal

Roche returned rights to RG7256 to Daiichi. The BRAF inhibitor was in Phase I testing to treat BRAF mutation-positive melanoma. Roche had rights to the compound from Plexxikon Inc., which Daiichi a...